Oncology Targeted Therapies
DAC discovers and develops proprietary small molecule drugs for the treatment of cancer. DACís research focuses on identifying agents with best-in-class properties able to specifically target distinct molecular pathways involved in the modulation of cancer.
Created by in 2004 by Genextra S.p.A.
, DAC has since then built a strong and experienced team in the epigenomics field. Given the high level of expertise in this area, DACís core activity is currently focused on identifying new HDAC and HSP90 inhibitors with best-in-class anti-tumor properties.
For more information on DAC's scientific programmes visit us at